๐๏ธ Verified NIH Record โข Updated 2025-09-09
Longitudinal Endpoint Assessment of Disease Burden in HD (NCT06475898)
๐ข Recruiting Interventional Protocol ๐ Observational Clinical Research Sponsor: Huntington Study Group
๐ฉบ Plain-English Summary (8th-Grade Level)
LEAD-HD is intended to collect and analyze self-reported health information from individuals with Huntington Disease (HD) or prodromal HD participating in a 24-month longitudinal natural history study using remote technologies.
Who can join: Review the eligibility criteria below.
Location: Huntington Study Group โ Rochester, New York
Age range: 18 Years
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (1 Sites)
- Huntington Study Group โ Rochester, New York
๐ Contact the Study Coordinator
Phone: (800) 487-7671
Email: info@myhdstory.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Huntington Disease
- Neurobiological Predictors of Huntington's Disease (PREDICT-HD) โ Iowa City, Iowa
- Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease โ Nashville, Tennessee
- GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease โ Birmingham, Alabama
- An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease (HD) โ Clayton,
- Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3) โ Charlottesville, Virginia
- Multi-Modal Digital Monitoring of Disease Symptoms Huntington's Disease โ Rochester, New York
Explore by condition: All Huntington Disease clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.